Post by Millie Nelson

“Our Series B strategy was centered on building a high-quality syndicate of investors who share Ona’s core vision: translating outstanding science into first-in-class medicines that can make a meaningful difference for patients,” Valerie Vanhooren, CEO and co-founder of ONA Therapeutics, told BioXconomy. “From the outset, we were selective in choosing partners who not only provide capital, but who also have expertise in oncology drug development and a strong conviction in the scientific foundations of Ona.” Read the full piece about this Series B funding by clicking the link below 🚀 https://lnkd.in/eVpYnHgW